AIFF - Firefly Neuroscience, Inc. Debt to Book Capitalization Ratio

Corporate company logo of Firefly Neuroscience Inc (AIFF)

The current balance sheet leverage ratio complements the data on the implementation of AI diagnostics for neurology. The scalability of the BNA cloud platform allows for the expansion of the client base without capital expenditures. However, digital sovereignty and cyber threats necessitate significant spending on data protection. The value of 0.00 reflects the metric's balance, linking the total liabilities of Firefly Neuroscience, Inc (AIFF) to its market value.

Firefly Neuro (AIFF) - Debts to Book Value from 07/04/2022 to 10/28/2026

Firefly Neuroscience, Inc. (AIFF) - metric breakdowns and financial figures

- price and consensus price forecast:
Stock Quotes Firefly Neuroscience, Inc|AIFF - Analyst Consensus Forecast
- market capitalization data:
Market Value AIFF|AIFF - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share Firefly Neuroscience|AIFF - Total Stockholders' Equity|Market Capitalization to Book Value Ratio fireflyneuro.com|AIFF - Total Asset Value of Company
- debt and liquidity data:
Total Debt to Capital Firefly Neuroscience, Inc|AIFF - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Firefly Neuroscience Inc|AIFF - Aggregate Debt Obligations|Debts to Book Capitalization AIFF
Fundamental company analysis:Firefly Neuroscience, Inc - AIFF
Brand item of Firefly Neuroscience Inc

Firefly Neuroscience, Inc (AIFF) is investing in the commercialization of AI tools for EEG analysis and brain diagnostics. This debt-to-equity ratio measures the proportion of borrowed funds within the equity structure. An increase in this coefficient signals heightened financial leverage and a risk of liquidity shortages. This chart reflects the daily shift in the balance between liabilities and assets. High leverage levels may limit market capitalization.

Competitors of Firefly Neuroscience, Inc

Debt to Book Value BIIB (Biogen Inc.)|neurocrine.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited (RGC)|AXSM: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACAD|Xenon Corp (XENE) - Debts to Book Value|Debts to Book Capitalization Viking Therapeutics VKTX|Debts to Book Capitalization Ratio supernus.com|CPRX (Catalyst Pharmaceuticals, Inc.) - Debts to Book Capitalization|Debts to Net Assets DNLI (Denali)|Debt to Book Capitalization Ratio Harmony Pharma|Debt to Net Assets Ratio Biohaven Corp BHVN|AMLX (Amylyx Pharmaceuticals) - Debts to Book Capitalization|TRVI - Debts to Book Value|Debts to Book Capitalization Praxis Precision Medicines, Inc. (PRAX)|AVXL (Anavex) - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio CeriBell Corp|Debt to Book Capitalization Ratio prothena.com (PRTA)|Alector, Inc. - Debt to Book Value|Debts to Book Value annexonbio.com ANNX|Debt to Book Value Omeros|Neurogene Inc - Debt to Net Assets Ratio|AC Immune Corp (ACIU) - Debt to Book Capitalization Ratio|VYGR - Debt to Book Value Ratio|Debts to Book Capitalization NMRA|Debts to Book Value scilexholding.com|TVGN (Tevogen Bio) - Debt to Book Value|Debts to Book Capitalization ACOG|Cognition Therapeutics (CGTX) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio IKT (Inhibikase Pharma)|SAVA: Debt to Book Capitalization Ratio|Assertio Holdings - Debts to Book Value|Debt to Book Capitalization Ratio COYA (Coya)|VTGN - Debts to Net Assets|OVID (ovidrx.com) - Debts to Book Capitalization|Acumen Pharmaceuticals, Inc (ABOS) - Debt to Book Value|CRVO: Debts to Book Capitalization|Debts to Net Assets Alterity Therapeutics Ltd|Clene Inc. - Debts to Book Capitalization|Debts to Book Value PEPG (pepgen.com)|JUNS - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Relmada Corp RLMD|ANVS: Debts to Book Capitalization|GRCE - Debt to Book Value|Debts to Book Capitalization KLTO|Debts to Book Value NeuroSense Therapeutics Ltd.|RVPH - Debt to Book Value|Debt to Net Assets Ratio MetaVia, Inc.|NRXS (NeurAxis, Inc.) - Debts to Book Capitalization|Debts to Net Assets HSDT (heliusmedical.com)|PASG - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Neuphoria Therapeutics, Inc. NEUP|NERV: Debts to Book Capitalization|ATHA - Debt to Book Value|ADXN: Debts to Book Capitalization|Alzamend Neuro (ALZN) - Debts to Book Capitalization|CYCN: Debts to Book Capitalization|Debts to Net Assets Protagenic|KTTA - Debts to Book Capitalization|Debts to Book Capitalization Ratio cortigent.com (CRGT)|Avenue Therapeutics (ATXI) - Debts to Book Capitalization|brainstorm-cell.com - Debts to Book Capitalization Ratio|Cara Therapeutics (CARA) - Debt to Book Capitalization Ratio|CHRO - Debt to Book Value Ratio|Debts to Book Capitalization ELYM|Debts to Book Value Intra-Cellular Therapies, Inc.|LBPH (Longboard Pharmaceuticals) - Debt to Book Value|Debts to Book Capitalization MRNS|NKGen Biotech (NKGN) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio NRBO (NeuroBo Pharmaceuticals Inc)|SAGE: Debt to Book Capitalization Ratio|Debts to Book Value Synaptogenix, Inc SNPX|Debts to Book Capitalization Trevena, Inc.|VIGL - Debts to Book Capitalization Ratio|Anew Medical - Debts to Book Capitalization|CERE (Cerevel Therapeutics Inc) - Debts to Net Assets